Norway· NO-ID_1E896089-699A-49AF-9A3F-560227F67F00

Rifinah

A rifampicin and isoniazid product containing isoniazid + rifampicin, registered in Norway by sanofi-aventis (2). The same ATC class is registered in 9 of our 19 countries.

ATC J04AM02

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedRifinahATCJ04AM02REGISTER NO.NO-ID_1E896089-699A-4…PACKS LISTED2CHECKEDSeptember 25, 2026

Where it is registered

Rifampicin and isoniazid is registered in 9 of 19 countries.

Countries holding a registration under ATC J04AM02 (rifampicin and isoniazid), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 5 of them publish a price we can compare per daily dose

Rifampicin and isoniazid · ATC J04AM02

9 / 19 countries

  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FEST (Norway)
Active substance
Isoniazid + Rifampicin
Manufacturer
sanofi-aventis (2)
Country
Norway (NO)
ATC code
J04AM02
ATC class
Rifampicin and isoniazid
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 2

  • no_merkevare_id
    ID_1E896089-699A-49AF-9A3F-560227F67F00
  • no_varenummer
    249748
    84

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

61 interactions on record for rifampicin and isoniazid.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rifampicin and isoniazid · interactions on record

61 records

61 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Rifampicin and isoniazid in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rifampicin and isoniazid products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Austria · Rifoldin Mit Inh
  • Cyprus · Rifamazid
  • Denmark · Rimactazid
  • Spain · Rifinah
  • France · Rifinah
  • United Kingdom (Northern Ireland) · Rifinah
  • Greece · Rifinah
  • Hungary · Rifazid
  • Ireland · Rifinah
  • Italy · Rifinah
  • Lithuania · Rifamazid
  • Netherlands · Rifinah
  • Poland · Rifamazid
  • Portugal · Rifinah
  • Romania · Sinerdol Iso
  • Sweden · Rimactazid
  • Slovenia · Rifinah

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a901da24-43d6-4715-9ed0-bd52ef377055
GET /v1/drugs/a901da24-43d6-4715-9ed0-bd52ef377055?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablett",
  "source": "fest",
  "status": "A",
  "atc_name": "Rifampicin og isoniazid",
  "merkevare_id": "ID_1E896089-699A-49AF-9A3F-560227F67F00",
  "name_form_strength": "Rifinah tab 150 mg/100 mg",
  "prescription_group": "C"
}

See everything about rifampicin and isoniazid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.